ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Develop and assessment of a predictive model for the first-course efficacy of acute myeloid leukemia].
Abstract readEnglish Abstract
In one paragraph
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
F ZhuDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhoushan Hospital, Zhoushan 316000, China.
Y L ZhouDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
Y ZhangDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
L P MaoDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
D ZhouDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
L Y MaDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
C M YangDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
W J YuDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
X N YeDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
J Y WeiDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
H T MengDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
M YangDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
W Y MaiDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
J J QianDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
Y L RenDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
Y J LouDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
J HuangDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
G X XuDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China.
W Z XieDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
H Y TongDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
H F WangDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
J JinDepartment of Hematology, First Affiliated Hospital, Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310000, China Zhejiang University Cancer Center, Hangzhou 310000, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteAdolescentAdultAgedCCAAT-Enhancer-Binding ProteinsFemaleHumansInduction ChemotherapyLogistic ModelsMaleMiddle AgedMutationPrognosisRemission InductionROC CurveCCAAT-Enhancer-Binding ProteinsEfficacy of the first courseLeukemia, myeloid, acutePredictive model
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.